A preprint reports that two proteins, WIF1 and FGF2, directed mouse skeletal stem cells to form cartilage resembling articular cartilage; the same type of cartilage grew in two-year-old mice and mice with osteoarthritis
A preprint reports that two proteins, WIF1 and FGF2, directed mouse skeletal stem cells to form cartilage resembling articular cartilage; the same type of cartilage grew in two-year-old mice and mice with osteoarthritis
On November 6, laboratories at Stanford University and the University of California, Davis, posted a preprint, a paper that has yet to undergo peer review, on bioRxiv about the stem cells that form bone and cartilage. The authors used the Panx3 gene to label these cells in mice and track their fate after joint surgery.
Adult articular cartilage has little capacity to regenerate. In a procedure called microfracture, a surgeon punctures the bone beneath the cartilage to allow bone marrow to reach the injury. Charles Chan, who isolated the mouse skeletal stem cell in 2015, said in 2020:
“Microfracture produces what is known as fibrocartilage, which resembles scar tissue more than true cartilage. It covers the bone and is better than nothing, but it lacks the springiness and elasticity of true cartilage and breaks down fairly quickly.”
That same year, Chan's laboratory showed that microfracture activates stem cells in mice and that a pair of proteins keeps them at the cartilage stage of their progression toward bone. Chan died on March 12, 2024, but is listed as one of the preprint's three senior authors.
To identify these cells, the authors compared gene activity in three mouse tissues: the growth plate (cartilage at the ends of bones), the callus that forms after a fracture, and articular cartilage. Panx3 was active in the growth plate and fracture callus, where stem cells are active, and silent in articular cartilage. The mice were engineered so that tamoxifen switches on a red label in cells expressing Panx3 and their descendants. After one day, about 90% of the labeled cells were skeletal stem cells or their immediate descendants.
Stem cells in which Panx3 was inactive were transplanted into mice that do not reject foreign cells. The transplanted cells activated Panx3 and produced their full range of descendants. Panx3 therefore marks an active state that a cell can enter.
To track the fate of these cells after microfracture, the authors placed a hydrogel containing CCN3, a protein that stimulates bone growth, at the injury site. Cells that activated Panx3 shortly after surgery mainly contributed to the bone beneath the cartilage. When a toxin was used to eliminate cells expressing Panx3, cartilage formation in response to CCN3 fell sharply, showing that these cells are needed for repair.
The authors hypothesized that the cells' surroundings determine their fate and looked for signals in articular cartilage, which remains cartilage and does not express Panx3. The genes encoding WIF1 and FGF2 are active in young mouse joints. FGF2 disappears as the mice mature, and WIF1 protein is detectable only in two-week-old mice. In culture, FGF2 suppressed the stem cells' ability to form bone and increased cartilage matrix production. Combining it with WIF1 increased matrix production further.
The authors reintroduced these signals into adult joints during microfracture. Without the proteins, the injury filled with fibrous tissue. Either protein alone produced cartilage that was progressing toward bone formation. With both proteins, cartilage resembling articular cartilage had formed after four weeks, as assessed by tissue staining and the presence of aggrecan, a cartilage protein. Red-labeled cells contributed to this cartilage, whereas with CCN3 they contributed to bone.
With both proteins, the same type of cartilage formed in one-year-old and two-year-old mice and in mice with osteoarthritis, joint wear caused by surgery on a meniscal ligament. In the mice with osteoarthritis, the cartilage persisted for up to 20 weeks. Skeletal stem cells from patients, transplanted into mice that do not reject foreign cells, produced aggrecan-containing cartilage cells after eight weeks only when both proteins were supplied. The authors conclude that “acquiring a regenerative stem cell state and determining the cell's subsequent fate are separable processes.”